国家集中带量采购政策下样本医院良性前列腺增生治疗药物使用情况分析  

Analysis on the use of medicines in treatment of benign prostatic hyperplasia in sample hospitals under the national volume-based procurement policy

作　　者：李锐 张倩倩 王瑞冬 高小峰 LI Rui;ZHANG Qianqian;WANG Ruidong;GAO Xiaofeng(Department of Urology,The First Affiliated Hospital of Naval Medical University,Shanghai 200433,China;Department of Pharmacy,Luodian Hospital,Baoshan District,Shanghai 201908,China;Clinical Research Center,The Third Affiliated Hospital of Naval Medical University,Shanghai 200438,China)

机构地区：[1]海军军医大学第一附属医院泌尿外科,上海200433 [2]上海市宝山区罗店医院药剂科,上海201908 [3]海军军医大学第三附属医院临床研究中心,上海200438

出　　处：《药学实践与服务》2025年第1期41-46,共6页Journal of Pharmaceutical Practice and Service

摘　　要：目的探讨国家药品集中带量采购等政策对良性前列腺增生(BPH)治疗药物使用的影响,为临床合理使用BPH治疗药物提供数据支撑。方法从全国医药信息网中提取2019至2023年样本医院良性前列腺增生治疗药物的使用数据(涉及892家医院,包括三级医院645家、二级医院247家),分析并比较该类药物的使用金额、用药频度(DDDs)、限定日费用(DDDc)、排序比(B/A)等指标的变化情况。结果受相关政策影响,样本医院BPH治疗药物的使用金额呈先大幅下降后平稳上升的趋势、DDDs总体呈逐年上升趋势,而DDDc总体呈逐年降低趋势;坦索罗辛和非那雄胺的DDDs在该类药物中持续排名前2位;坦索罗辛的B/A值显著高于其他BPH治疗药物。结论2019至2023年,因国家药品集采等政策的实施,切实减轻了良性前列腺增生患者的经济负担。在α受体阻滞剂和5α还原酶抑制剂两种分类中B/A最高的坦索罗辛和非那雄胺占据BPH治疗药物的市场主导地位,从经济性角度看,良性前列腺增生治疗药物的临床使用相对合理。Objective To explore the impact of national volume-based procurement policies on the use of medicines in treatment of benign prostatic hyperplasia(BPH)and provide data support for the rational clinical use of medicines in BPH treatment.Methods Data on the use of BPH treatment medications from 2019 to 2023 were extracted from the Chinese Medicine Economic Information Network(CMEI),covering 892 hospitals(including 645 tertiary hospitals and 247 secondary hospitals).The changes in various indicators,including the consumption sum,Defined daily doses(DDDs),Defined daily dose cost(DDDc),and the ranking ratio(B/A)of these drugs were analyzed and compared.Results From 2019 to 2023,due to the influence of relevant policies,the overall consumption sums of medicines used in the sample hospitals in BPH treatment showed a trend of decreasing first and then rising steadily.The DDDs showed an overall upward trend,while the DDDc demonstrated a gradual decline.Tamsulosin and finasteride consistently ranked first and second in DDDs.The B/A value for tamsulosin was significantly higher than that of other BPH treatment medications.Conclusion The implementation of national centralized drug volume-based procurement policies and other policies from 2019 to 2023 had effectively reduced the economic burden of patients with benign prostatic hyperplasia.Tamsulosin and finasteride,which had the highest B/A in the two categories ofα-blockers and 5α-reductase inhibitors,dominated the market for BPH treatment.The clinical use of BPH treatment medications was relatively rational.

关 键 词：国家药品集中带量采购政策 良性前列腺增生药物 用药频度 限定日费用 

分 类 号：R69[医药卫生—泌尿科学]